Aurobindo Pharma Ltd has received USFDA approval for acetylcysteine injection. The product is expected to be launched in the first quarter of 2016-17. The drug acetylcysteine injection is bioequivalent and therapeutically equivalent to the reference listed drug product Acetadote of Cumberland Pharmaceuticals Inc and is indicated to prevent or lessen hepatic injury. The approved product has an estimated market size of $28 million for the 12 months ended December 2015.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply